Introduction
We recently described a thyroxine-binding plasma prealbumin (transthyretin) variant that was isolated from amyloid fibrils in hereditary amyloidosis of Swedish origin (1) . This variant protein has a single amino acid change, a methionine for valine at position 30 from the amino terminus. A similar finding was reported for the subunit protein of hereditary amyloid in Japan and also for hereditary amyloid from Portugal (2, 3) .
In the amyloid patients of Swedish origin, both normal and variant forms of prealbumin are found in the amyloid fibrils and in the plasma of affected individuals (4) . Since it is likely that circulating prealbumin is the precursor of the amyloid fibril subunit protein, it is logical that the variant prealbumin would be present in the plasma of individuals before they reach the age of usual onset of amyloidosis symptoms. To 
Results
The plasma concentrations of prealbumin for each of the four subjects of this study are listed in Table I with the yields from 100 ml of plasma from each. The yield of 35-50% of theoretical for the three-stage procedure of prealbumin isolation is more than adequate to give the amount of protein from 100 ml of plasma that is necessary for the chemical analyses. As little as 10 ml of plasma would suffice.
Separation of CNBr peptides by HPLC gave two easily distinguished patterns. Pattern one, which is identical to CNBrdegraded normal prealbumin from an individual without a family history of amyloidosis, shows two major peptides (Fig.  2 A) . This pattern was seen with two of the prealbumin preparations (subjects 2 and 3). Pattern two (Fig. 2 B) was seen with the other two individuals (1 and 4) and showed four peptides. This is consistent with those prealbumin preparations containing a mixture of normal prealbumin, which gives two peptides, and the variant prealbumin, which has two methionines and gives three peptides (including the normal amino terminal peptide). All the peptides from one of the prealbumins showing pattern two (Fig. 2 B) were isolated and subjected to sequence analysis. CNBr peak 1 (CB1) gave a sequence Gly-Pro-Thr, which identifies it as the amino terminal peptide. CNBr peak 2 (CB2) gave a sequence of Val-Lys-Val, which is consistent with the normal prealbumin sequence from positions 14-127. Gly (3)* Pro (1) Thr (1) 1-13 CB2 9
Val (8) Lys (6) Val (6) 14-127 CBVI 7 Val (5) Lys (3) Val (4) 14-30 CBV2 6
His (2) Val (5) Phe (5) 30-127 * Yield in nanomoles.
variant peak 2 (CBV2) gave the sequence His-Val-Phe, which is consistent with it being derived from the cleavage at methionine in position 30 of the variant prealbumin. Step I Step 2 Step 3 Step (Fig. 3) . Table 111 .
To evaluate the sensitivity of the HPLC method of identifying the variant prealbumin, mixing experiments using normal and variant prealbumin preparations were done. From the sequenator yield data (Table III) , it was determined that the prealbumin preparation from subject 4 contained 35% variant prealbumin. This is consistent with the yields of normal and variant tryptic peptides from the prealbumin of an individual with FAP type I (1). A CNBr-treated preparation of prealbumin from subject 4 was serially diluted with known amounts of CNBr-cleaved normal prealbumin to generate mixtures with decreasing concentrations of the two variant peptides (CBVI and CBV2). Analysis of each dilution by HPLC revealed that the peak at 42 min representing CBV2 (Fig. 2 B) could be identified in samples having as little as 1% variant peptide.
Discussion
In all cases of autosomal dominant heredofamilial amyloidosis that have been studied biochemically, prealbumin has been found to be the subunit protein of the fibril. This includes two Swedish kindreds (6, 1 1), a Japanese kindred (2), Portuguese patients with FAP type I (3, 12) , the Indiana-Swiss kindred with FAP type 11 (13) , and a lone Israeli with an unclassified form of amyloidosis (14) . It is known that the prealbumin from the Swedish family that we have studied is a variant having a methionine substitution for the valine at position 30 from the amino terminus (4). The same finding has been reported for amyloid from one Japanese family (2) , and a recent study shows the same variant prealbumin in the Portuguese amyloid (15) . The prealbumin isolated from amyloid of the one Israeli patient had a glycine-threonine interchange at position 49 of the molecule (14) . Both the Swedish and Israeli amyloid proteins have been completely sequenced and shown to have just one amino acid substitution each. While the complete sequence of the Portuguese amyloid protein has not been reported, there are no data to suggest that it has more than the one substitution (15) . Preliminary studies on amyloid from the Indiana-Swiss kindred with FAP type II show that this type of amyloid does not contain the variant prealbumin with an extra methionine residue.
Since all of the autosomal dominant heredofamilial amyloidoses that have been described become clinically apparent after the start of the reproductive years, the only assured way that an individual at risk for developing the disease can prevent passage of the aberrant gene to his/her children has been to elect not to have children. This is not a viable alternative to many individuals. In addition, increased dissemination of aberrant prealbumin genes has become obvious from the studies of several kindreds. While high infant mortality and early death for patients with peripheral neuropathy from infected leg ulcers markedly decreased the size of reproductive family units in the 19th and early 20th centuries, modern medicine has increased the likelihood that the amyloid gene will be preserved in an increasing number of families. This has been balanced somewhat by the trend toward smaller family size. (17), and additional large kindreds in Japan (18) . Application of this methodology, which is very sensitive and relatively easy, to the Japanese and Portuguese families with amyloidosis that have the same genetic defect, could have major impact on genetic counseling. In addition, the ability to identify carriers long before the onset of symptoms may allow the study of possible modulating factors that may play a role in the differences seen in expression (particularly age of onset) of the disease.
